Landing a Deal with Big Pharma
Big pharma companies are investing heavily in external innovation, searching for licensing deals and acquisition targets in the biotech industry.
Due to pending losses of exclusivity and an uncertain policy environment, pharma companies are seeking to make strategic investments that yield significant returns.
“I think what we're seeing is, yes, there's capital, but it's isolated to a more select group of biotech companies,”
according to Steven Ladd, vice president of business development and acquisitions at BeOne Medicines.
- Biotech companies with differentiated data are more likely to attract large pharma interest.
- Start-ups face challenges, but this can also create opportunities for both parties.
Author's summary: Big pharma seeks innovative biotech deals.
More News
- Ayuba Sylvester James: “For MCP to Rise, Chakwera Must Fall” - Malawi Nyasa Times - News from Malawi about Malawi
- Weekly Recap: 13 Health Press Releases You Need to See
- Samsung taps Nvidia GPUs for AI factory
- Thailand's First MINISO LAND Store Opens, Bringing Experiential IP-based Store Design to Bangkok
- ‘Tyrant’ teaser hints at Charlize Theron’s boldest role yet in Amazon’s intense thriller
- NYT Mini crossword answers, hints for October 31, 2025
- The unified linkage model: A new lens for understanding cyber risk
- I got my tarot read at Halloweentown and apparently I’m healing
- Op-ed: Somerville Jews Say: Vote Yes on Question 3 - The Tufts Daily
- Kuaishou Technology to Report 2025 Third Quarter Financial Results on November 19, 2025